avn-101 avn-101 avn-101, a close structural analogue of latrepirdine, is a selective 5-ht6 receptor antagonist which is under development by avineuro pharmaceuticals for the treatment of alzheimer's disease and anxiety disorders. as of november 2013, it was in phase ii clinical trials for these indications. avn-101identifiers iupac name 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1h-pyridoindole cas number1025725-91-0 y 1061354-48-0 (hydrochloride)chemspider24643855unii6mhr5iv28schemblchembl592752chemical and physical dataformulac21h24n2molar mass304.437 g·mol−13d model (jsmol)interactive image smiles cc1ccc2c(c1)c3c(n2ccc4ccccc4)ccn(c3)c inchi inchi=1s/c21h24n2/c1-16-8-9-20-18(14-16)19-15-22(2)12-11-21(19)23(20)13-10-17-6-4-3-5-7-17/h3-9,14h,10-13,15h2,1-2h3key:ibuhddletpjvgp-uhfffaoysa-n